Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects
By LabMedica International staff writers Posted on 29 Jul 2015 |
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).
A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.
Mutations in mitochondrial DNA (mtDNA) can cause fatal or severely debilitating disorders with limited treatment options. Clinical manifestations vary based on mutation type and the relative levels of mutant and normal mtDNA within each cell.
Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) first described the situation of patients having both normal and mutated mtDNA. Skin cells from these patients could be turned into a population of stem cells, some with normal mtDNA and some with mutated mtDNA. It was then a simple matter to clone only the cells with normal mtDNA to form a population of normal pluripotent stem cells.
The other case centered on patients with few, if any cells with normal mtDNA. To solve this problem the investigators removed the nuclei of the patient's skin cells, which contain most of their genes, and transplanted them into donor egg cells with healthy mitochondria. The new egg cells were then used to generate healthy pluripotent stem cells.
Results published in the July 15, 2015, online edition of the journal Nature revealed that both reprogramming approaches offered complementary strategies for derivation of pluripotent stem cells containing exclusively normal mtDNA.
"Right now, there are no cures for mitochondrial diseases," said senior author Dr. Juan Carlos Izpisua Belmonte, professor of genetics at the Salk Institute. "Very recently, we have developed ways to prevent these diseases, so it was natural to next ask how we could treat them."
Related Links:
Salk Institute
Mutations in mitochondrial DNA (mtDNA) can cause fatal or severely debilitating disorders with limited treatment options. Clinical manifestations vary based on mutation type and the relative levels of mutant and normal mtDNA within each cell.
Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) first described the situation of patients having both normal and mutated mtDNA. Skin cells from these patients could be turned into a population of stem cells, some with normal mtDNA and some with mutated mtDNA. It was then a simple matter to clone only the cells with normal mtDNA to form a population of normal pluripotent stem cells.
The other case centered on patients with few, if any cells with normal mtDNA. To solve this problem the investigators removed the nuclei of the patient's skin cells, which contain most of their genes, and transplanted them into donor egg cells with healthy mitochondria. The new egg cells were then used to generate healthy pluripotent stem cells.
Results published in the July 15, 2015, online edition of the journal Nature revealed that both reprogramming approaches offered complementary strategies for derivation of pluripotent stem cells containing exclusively normal mtDNA.
"Right now, there are no cures for mitochondrial diseases," said senior author Dr. Juan Carlos Izpisua Belmonte, professor of genetics at the Salk Institute. "Very recently, we have developed ways to prevent these diseases, so it was natural to next ask how we could treat them."
Related Links:
Salk Institute
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples